Table 5.

Step-up strategies in patients experiencing endoscopic postoperative recurrence in the endoscopic management-based group

Number of patient	Treatment before endoscopic evaluation	Rutgeerts’ score	Treatment after endoscopic evaluation
1	None	i2	AZA
2	AZA	i3	IFX
3	AZA	i4	IFX
4	AZA	i2	AZA
5	AZA	i2	AZA (increased dose)
6	5-ASA	i4	IFX
7	ADA eow	i3	ADA ew
8	None	i4	ADA
9	5-ASA	i4	IFX + MTX
10	AZA	i4	IFX
11	AZA	i2	AZA (increased dose)
12	IFX + MTX	i3	IFX (increased dose) + MTX
13	ADA eow	i4	ADA ew
14	None	i2	AZA
15	None	i3	ADA
16	None	i2	AZA
17	None	i2	AZA
18	ADA eow	i3	ADA ew

AZA: Azathioprine; MTX: Methotrexate; IFX: Infliximab; ADA: Adalimumab; eow: Every other week; ew: Every week.